388 related articles for article (PubMed ID: 28960366)
1. Portal pressure and liver stiffness measurements in the prediction of fibrosis regression after sustained virological response in recurrent hepatitis C.
Mauro E; Crespo G; Montironi C; Londoño MC; Hernández-Gea V; Ruiz P; Sastre L; Lombardo J; Mariño Z; Díaz A; Colmenero J; Rimola A; Garcia-Pagán JC; Brunet M; Forns X; Navasa M
Hepatology; 2018 May; 67(5):1683-1694. PubMed ID: 28960366
[TBL] [Abstract][Full Text] [Related]
2. Effects of All-Oral Anti-Viral Therapy on HVPG and Systemic Hemodynamics in Patients With Hepatitis C Virus-Associated Cirrhosis.
Lens S; Alvarado-Tapias E; Mariño Z; Londoño MC; LLop E; Martinez J; Fortea JI; Ibañez L; Ariza X; Baiges A; Gallego A; Bañares R; Puente A; Albillos A; Calleja JL; Torras X; Hernández-Gea V; Bosch J; Villanueva C; Forns X; García-Pagán JC
Gastroenterology; 2017 Nov; 153(5):1273-1283.e1. PubMed ID: 28734831
[TBL] [Abstract][Full Text] [Related]
3. Improvement of liver stiffness measurement, acoustic radiation force impulse measurements, and noninvasive fibrosis markers after direct-acting antivirals for hepatitis C virus G4 recurrence post living donor liver transplantation: Egyptian cohort.
Alem SA; Said M; Anwar I; Abdellatif Z; Elbaz T; Eletreby R; AbouElKhair M; El-Serafy M; Mogawer S; El-Amir M; El-Shazly M; Hosny A; Yosry A
J Med Virol; 2018 Sep; 90(9):1508-1515. PubMed ID: 29718546
[TBL] [Abstract][Full Text] [Related]
4. Regression of liver fibrosis over a 24-week period after completing direct-acting antiviral therapy in patients with chronic hepatitis C receiving care within the national hepatitis C elimination program in Georgia: results of hepatology clinic HEPA experience.
Dolmazashvili E; Abutidze A; Chkhartishvili N; Karchava M; Sharvadze L; Tsertsvadze T
Eur J Gastroenterol Hepatol; 2017 Nov; 29(11):1223-1230. PubMed ID: 28857900
[TBL] [Abstract][Full Text] [Related]
5. Liver stiffness identifies two different patterns of fibrosis progression in patients with hepatitis C virus recurrence after liver transplantation.
Carrión JA; Torres F; Crespo G; Miquel R; García-Valdecasas JC; Navasa M; Forns X
Hepatology; 2010 Jan; 51(1):23-34. PubMed ID: 19839063
[TBL] [Abstract][Full Text] [Related]
6. Noninvasive Measurements Predict Liver Fibrosis Well in Hepatitis C Virus Patients After Direct-Acting Antiviral Therapy.
Huang R; Rao H; Yang M; Gao Y; Wang J; Jin Q; Ma D; Wei L
Dig Dis Sci; 2020 May; 65(5):1491-1500. PubMed ID: 31654313
[TBL] [Abstract][Full Text] [Related]
7. Non-invasive candidate protein signature predicts hepatic venous pressure gradient reduction in cirrhotic patients after sustained virologic response.
Richards SM; Guo F; Zou H; Nigsch F; Baiges A; Pachori A; Zhang Y; Lens S; Pitts R; Finkel N; Loureiro J; Mongeon D; Ma S; Watkins M; Polus F; Albillos A; Tellez L; Martinez-González J; Bañares R; Turon F; Ferrusquía-Acosta J; Perez-Campuzano V; Magaz M; Forns X; Badman M; Sailer AW; Ukomadu C; Hernández-Gea V; Garcia-Pagán JC
Liver Int; 2023 Sep; 43(9):1984-1994. PubMed ID: 37443448
[TBL] [Abstract][Full Text] [Related]
8. Non-invasive tests for clinically significant portal hypertension after HCV cure.
Semmler G; Lens S; Meyer EL; Baiges A; Alvardo-Tapias E; Llop E; Tellez L; Schwabl P; Mauro E; Escudé L; Díez C; Ibañez-Samaniego L; Puente Á; Fortea JI; Abadía M; Zanetto A; Conthe A; Hernandez-Évole H; Luzko Scheid IS; Jia J; Yoshiji H; Francque SM; Tsochatzis EA; Russo FP; Crespo G; Forns X; Bañares R; Villanueva C; Hernández-Gea V; Reiberger T; Bosch J; García Pagán JC; Mandorfer M;
J Hepatol; 2022 Dec; 77(6):1573-1585. PubMed ID: 36063968
[TBL] [Abstract][Full Text] [Related]
9. Clinical outcome and hemodynamic changes following HCV eradication with oral antiviral therapy in patients with clinically significant portal hypertension.
Lens S; Baiges A; Alvarado-Tapias E; LLop E; Martinez J; Fortea JI; Ibáñez-Samaniego L; Mariño Z; Rodríguez-Tajes S; Gallego A; Bañares R; Puente Á; Albillos A; Calleja JL; Torras X; Hernández-Gea V; Bosch J; Villanueva C; García-Pagán JC; Forns X
J Hepatol; 2020 Dec; 73(6):1415-1424. PubMed ID: 32535060
[TBL] [Abstract][Full Text] [Related]
10. Effect of viral suppression on hepatic venous pressure gradient in hepatitis C with cirrhosis and portal hypertension.
Afdhal N; Everson GT; Calleja JL; McCaughan GW; Bosch J; Brainard DM; McHutchison JG; De-Oertel S; An D; Charlton M; Reddy KR; Asselah T; Gane E; Curry MP; Forns X
J Viral Hepat; 2017 Oct; 24(10):823-831. PubMed ID: 28295923
[TBL] [Abstract][Full Text] [Related]
11. Impact of viral eradication with sofosbuvir-based therapy on the outcome of post-transplant hepatitis C with severe fibrosis.
Martini S; Sacco M; Strona S; Arese D; Tandoi F; Dell Olio D; Stradella D; Cocchis D; Mirabella S; Rizza G; Magistroni P; Moschini P; Ottobrelli A; Amoroso A; Rizzetto M; Salizzoni M; Saracco GM; Romagnoli R
Liver Int; 2017 Jan; 37(1):62-70. PubMed ID: 27344058
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness of direct-acting agents for hepatitis C and liver stiffness changing after sustained virological response.
Fernandes FF; Piedade J; Guimaraes L; Nunes EP; Chaves U; Goldenzon RV; Cardoso SW; Duarte J; Grinsztejn B; Veloso VG; Pereira G; Perazzo H
J Gastroenterol Hepatol; 2019 Dec; 34(12):2187-2195. PubMed ID: 31062880
[TBL] [Abstract][Full Text] [Related]
13. The usefulness of non-invasive liver stiffness measurements in predicting clinically significant portal hypertension in cirrhotic patients: Korean data.
Hong WK; Kim MY; Baik SK; Shin SY; Kim JM; Kang YS; Lim YL; Kim YJ; Cho YZ; Hwang HW; Lee JH; Chae MH; Kim HA; Kang HW; Kwon SO
Clin Mol Hepatol; 2013 Dec; 19(4):370-5. PubMed ID: 24459641
[TBL] [Abstract][Full Text] [Related]
14. High sustained virological response to pegylated interferon and ribavirin for recurrent genotype 3 hepatitis C infection post-liver transplantation.
Faisal N; Mumtaz K; Marquez M; Renner EL; Lilly LB
Hepatol Int; 2015 Jan; 9(1):76-83. PubMed ID: 25788382
[TBL] [Abstract][Full Text] [Related]
15. Sustained virologic response to interferon-free therapies ameliorates HCV-induced portal hypertension.
Mandorfer M; Kozbial K; Schwabl P; Freissmuth C; Schwarzer R; Stern R; Chromy D; Stättermayer AF; Reiberger T; Beinhardt S; Sieghart W; Trauner M; Hofer H; Ferlitsch A; Ferenci P; Peck-Radosavljevic M
J Hepatol; 2016 Oct; 65(4):692-699. PubMed ID: 27242316
[TBL] [Abstract][Full Text] [Related]
16. The diagnostic accuracy of Fibroscan for cirrhosis is influenced by liver morphometry in HCV patients with a sustained virological response.
D'Ambrosio R; Aghemo A; Fraquelli M; Rumi MG; Donato MF; Paradis V; Bedossa P; Colombo M
J Hepatol; 2013 Aug; 59(2):251-6. PubMed ID: 23528378
[TBL] [Abstract][Full Text] [Related]
17. Liver stiffness-based score in hepatoma risk assessment for chronic hepatitis C patients after successful antiviral therapy.
Wang JH; Yen YH; Yao CC; Hung CH; Chen CH; Hu TH; Lee CM; Lu SN
Liver Int; 2016 Dec; 36(12):1793-1799. PubMed ID: 27254286
[TBL] [Abstract][Full Text] [Related]
18. Impact of fibrosis progression on clinical outcome in patients treated for post-transplant hepatitis C recurrence.
Dhanasekaran R; Sanchez W; Mounajjed T; Wiesner RH; Watt KD; Charlton MR
Liver Int; 2015 Nov; 35(11):2433-41. PubMed ID: 26058570
[TBL] [Abstract][Full Text] [Related]
19. Non-invasive prediction of liver-related events in patients with HCV-associated compensated advanced chronic liver disease after oral antivirals.
Pons M; Rodríguez-Tajes S; Esteban JI; Mariño Z; Vargas V; Lens S; Buti M; Augustin S; Forns X; Mínguez B; Genescà J
J Hepatol; 2020 Mar; 72(3):472-480. PubMed ID: 31629779
[TBL] [Abstract][Full Text] [Related]
20. Liver stiffness 1 year after transplantation predicts clinical outcomes in patients with recurrent hepatitis C.
Crespo G; Lens S; Gambato M; Carrión JA; Mariño Z; Londoño MC; Miquel R; Bosch J; Navasa M; Forns X
Am J Transplant; 2014 Feb; 14(2):375-83. PubMed ID: 24410892
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
